Kiniksa Pharmaceuticals International, plc (KNSA) — Financial statements
Income statement, balance sheet, and cash flow for Kiniksa Pharmaceuticals International, plc — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 678↑60.1% | 423↑56.6% | 270↑22.7% | 220↑471.2% | 39 | |
| Cost of Revenue | 307↑404.7% | 61↑7.8% | 57↑146.9% | 23↑151.6% | 9 | |
| Gross Profit | 370↑2.2% | 362↑69.5% | 214↑8.3% | 197↑570.0% | 29 | |
| Operating Expenses | ||||||
| R&D Expenses | 97↓13.2% | 112↑46.7% | 76↑16.2% | 65↓34.0% | 99 | |
| General & Administrative Expenses | 0.00↓100.0% | 157 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00↓100.0% | 11 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 196↑16.8% | 168↑29.8% | 129↑32.1% | 98↑14.0% | 86 | |
| Other Expenses | 0.00↓100.0% | 128↑284.1% | 33↑38.8% | 24↑2782.8% | 0.84 | |
| Operating Expenses | 293↓28.2% | 408↑70.7% | 239↑27.4% | 188↑0.8% | 186 | |
| Total Costs & Expenses | 600↑28.0% | 469↑58.7% | 295↑40.4% | 210↑7.8% | 195 | |
| Operating Results | ||||||
| Operating Income | 77↑269.3% | -46↓81.0% | -25↓357.8% | 10↑106.2% | -157 | |
| Depreciation & Amortization | 2↓8.3% | 2↓27.6% | 2↓2.5% | 2↑2.0% | 2 | |
| EBITDA | 90↑305.9% | -44↓92.2% | -23↓287.7% | 12↑107.9% | -154 | |
| EBIT | 89↑294.8% | -46↓81.0% | -25↓357.8% | 10↑106.2% | -157 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00↓100.0% | 9↑10.8% | 9↑581.9% | 1↑1191.8% | 0.10 | |
| Interest Income | 0.00↓100.0% | 9↑10.8% | 9↑581.9% | 1↑1191.8% | 0.10 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | -12 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 12↑23.1% | 9↑10.8% | 9↑581.9% | 1↑1191.8% | 0.10 | |
| Income Before Tax | 89↑345.8% | -36↓117.1% | -17↓251.0% | 11↑107.0% | -157 | |
| Income Tax Expense | 30↑324.1% | 7↑122.9% | -31↑82.2% | -172↓12543.1% | 1 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 59↑236.6% | -43↓406.7% | 14↓92.3% | 183↑216.1% | -158 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 59↑236.6% | -43↓406.7% | 14↓92.3% | 183↑216.1% | -158 | |
| Bottom-Line Net Income | 59↑236.6% | -43↓406.7% | 14↓92.3% | 183↑216.1% | -158 | |
| EPS (Basic) | 0.80↑233.3% | -0.60↓400.0% | 0.20↓92.4% | 2.64↑214.8% | -2.30 | |
| EPS (Diluted) | 0.75↑225.0% | -0.60↓400.0% | 0.20↓92.3% | 2.60↑213.0% | -2.30 | |
| Weighted Average Shares | 74↑3.9% | 71↑1.9% | 70↑1.0% | 69↑1.2% | 69 | |
| Weighted Average Diluted Shares | 79↑10.6% | 71↓0.7% | 72↑2.1% | 70↑2.7% | 69 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.